<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002802</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000064902</org_study_id>
    <secondary_id>GER-NB90</secondary_id>
    <secondary_id>EU-96004</secondary_id>
    <nct_id>NCT00002802</nct_id>
  </id_info>
  <brief_title>Therapy Based on Stage of Disease and Risk Assessment in Treating Children With Neuroblastoma</brief_title>
  <official_title>PHASE III MULTICENTRE TRIAL OF TREATMENT OF NEUROBLASTOMA IN CHILDREN AND ADOLESCENTS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital Medical Center, Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Combining chemotherapy with bone marrow transplantation may allow&#xD;
      the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. Radiation&#xD;
      therapy uses high-energy x-rays to damage tumor cells. It is not yet known which treatment&#xD;
      regimen is most effective in treating patients with different stages of and risk factors for&#xD;
      neuroblastoma.&#xD;
&#xD;
      PURPOSE: Phase III trial to study the effectiveness of therapy based on stage of disease and&#xD;
      risk assessment in treating children with neuroblastoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Increase the survival rates and duration of survival in children and&#xD;
      adolescents with neuroblastoma by using stage- and risk group-appropriate therapy. II.&#xD;
      Determine whether using cisplatin/etoposide/vindesine and&#xD;
      vincristine/dacarbazine/ifosfamide/doxorubicin instead of cisplatin/teniposide and&#xD;
      vincristine/dacarbazine/cyclophosphamide/doxorubicin improves remission rate and lessens&#xD;
      toxicity in patients with stage 3C, 3D, or 4 neuroblastoma. III. Determine whether local&#xD;
      radiotherapy to the primary tumor and bone metastasis improves local tumor control in these&#xD;
      patients. IV. Compare the efficacy and survival associated with short-term, high-dose&#xD;
      conditioning chemotherapy plus autologous bone marrow transplantation vs. long-term, low-dose&#xD;
      cytostatic chemotherapy as consolidation therapy in these patients. V. Determine whether&#xD;
      early use of low-dose doxorubicin/vincristine plus hepatic irradiation slows disease&#xD;
      progression in patients with stage 4S-C neuroblastoma. VI. Determine whether 4 courses of&#xD;
      chemotherapy reduces the occurrence of local and systemic relapse in patients with stages 2,&#xD;
      3A, and 3B neuroblastoma. VII. Determine whether serum tumor markers (LDH, catecholamine&#xD;
      metabolites, and neuron-specific enolase) are predictive of remission behavior.&#xD;
&#xD;
      OUTLINE: Patients are staged according to the International Neuroblastoma Staging System and&#xD;
      are further defined by progressively less favorable risk groups based on age at diagnosis,&#xD;
      serum LDH, and tumor resectability (risk groups A, B, C, and D, representing presence of 0,&#xD;
      1, 2, or 3 risk factors, respectively). Patients who are unable to be resected at entry or&#xD;
      with incomplete resection are re-evaluated at 4-month intervals for the appropriateness of&#xD;
      tumor resection. STAGE 1 PATIENTS Patients undergo complete primary tumor resection and no&#xD;
      other therapy. STAGES 2, 3A, AND 3B PATIENTS Patients undergo primary tumor resection,&#xD;
      followed by cisplatin, etoposide, vindesine (PEV) alternating monthly with vincristine,&#xD;
      dacarbazine, ifosfamide, doxorubicin (VDIA). Patients in complete remission (CR) discontinue&#xD;
      therapy, while those with less than CR receive additional therapy as outlined below for&#xD;
      stages 3C, 3D, and 4 patients, except that these patients are not eligible for bone marrow&#xD;
      transplantation. STAGES 3C, 3D, AND 4 PATIENTS Patients receive PEV and VDIA as above, with&#xD;
      radiotherapy to sites of metastases during the third and fourth courses, following which&#xD;
      autologous bone marrow is collected. Following marrow harvest, patients receive up to 4 more&#xD;
      alternating courses of PEV/VDIA; those with no response or progressive disease after the&#xD;
      sixth chemotherapy course are referred for other therapy. Patients who complete PEV/VDIA&#xD;
      receive 3 weeks of radiotherapy to the primary tumor bed or residual tumor. Stage 4 patients&#xD;
      in complete or very good partial remission and with sufficient harvested marrow undergo ABMT&#xD;
      following radiotherapy. Myeloablation consists of high-dose MIBG radioisotope therapy&#xD;
      followed by high-dose melphalan, etoposide, and carboplatin. All other patients and those who&#xD;
      refuse ABMT receive 1 year of alternating, low-dose chemotherapy courses, beginning&#xD;
      concurrently with initiation of radiotherapy. One regimen consists of oral&#xD;
      melphalan/etoposide for 5 days and the other regimen consists of intravenous vincristine on 1&#xD;
      day and oral cyclophosphamide for 7 days. Therapy continues for 1 year. STAGE 4S PATIENTS&#xD;
      Patients in risk groups 4S-A and 4S-B receive no therapy. Patients in group 4S-C receive 4-8&#xD;
      weekly injections of doxorubicin and vincristine (AV). Patients with tumor progression may&#xD;
      receive low-dose radiotherapy. Primary tumor resection may be delayed up to 8 months after&#xD;
      diagnosis in these patients. Use of G-CSF is allowed but not recommended.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 500 patients will be accrued on this multicenter study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 1990</start_date>
  <completion_date type="Actual">September 2003</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Neuroblastoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dacarbazine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ifosfamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mesna</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine sulfate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vindesine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>autologous bone marrow transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>low-LET cobalt-60 gamma ray therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>low-LET electron therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>low-LET photon therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radioisotope therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Neuroblastoma with diagnosis based on one of the following:&#xD;
        Histologic confirmation Cytologic confirmation in bone marrow and elevated catecholamine&#xD;
        metabolites Typical tumor appearance on CT, MRI, or ultrasound and: Unequivocal MIBG uptake&#xD;
        in tumor Elevated catecholamines in serum or urine No primitive neuroectodermal tumor or&#xD;
        primary intracerebral neuroblastoma Such patients referred to protocol GER-HIT90&#xD;
&#xD;
        PATIENT CHARACTERISTICS: Age: Under 21 Other: No serious cerebral trouble No severe&#xD;
        concomitant disease, e.g.: No severe congenital malformation No severe organ function&#xD;
        abnormality&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY: No prior cytostatic therapy (e.g., for Wilms' tumor) No&#xD;
        concurrent therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>20 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank Berthold, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Children's Hospital Medical Center, Cincinnati</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Cologne</name>
      <address>
        <city>Frechen</city>
        <zip>DOH-5-0226</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Krams M, Hero B, Berthold F, Parwaresch R, Harms D, Rudolph P. Proliferation marker KI-S5 discriminates between favorable and adverse prognosis in advanced stages of neuroblastoma with and without MYCN amplification. Cancer. 2002 Feb 1;94(3):854-61.</citation>
    <PMID>11857322</PMID>
  </reference>
  <reference>
    <citation>Simon T, Hero B, Dupuis W, Selle B, Berthold F. The incidence of hearing impairment after successful treatment of neuroblastoma. Klin Padiatr. 2002 Jul-Aug;214(4):149-52. doi: 10.1055/s-2002-33179.</citation>
    <PMID>12165893</PMID>
  </reference>
  <reference>
    <citation>Berthold F, Hero B, Kremens B, Handgretinger R, Henze G, Schilling FH, Schrappe M, Simon T, Spix C. Long-term results and risk profiles of patients in five consecutive trials (1979-1997) with stage 4 neuroblastoma over 1 year of age. Cancer Lett. 2003 Jul 18;197(1-2):11-7. doi: 10.1016/s0304-3835(03)00076-4.</citation>
    <PMID>12880954</PMID>
  </reference>
  <reference>
    <citation>von Schweinitz D, Hero B, Berthold F. The impact of surgical radicality on outcome in childhood neuroblastoma. Eur J Pediatr Surg. 2002 Dec;12(6):402-9. doi: 10.1055/s-2002-36952.</citation>
    <PMID>12548494</PMID>
  </reference>
  <results_reference>
    <citation>Simon T, Hero B, Hunneman DH, Berthold F. Tumour markers are poor predictors for relapse or progression in neuroblastoma. Eur J Cancer. 2003 Sep;39(13):1899-903. doi: 10.1016/s0959-8049(03)00376-9.</citation>
    <PMID>12932669</PMID>
  </results_reference>
  <results_reference>
    <citation>Haberle B, Hero B, Berthold F, von Schweinitz D. Characteristics and outcome of thoracic neuroblastoma. Eur J Pediatr Surg. 2002 Jun;12(3):145-50. doi: 10.1055/s-2002-32721.</citation>
    <PMID>12101494</PMID>
  </results_reference>
  <results_reference>
    <citation>Hero B, Hunneman DH, Gahr M, Berthold F. Evaluation of catecholamine metabolites, mIBG scan, and bone marrow cytology as response markers in stage 4 neuroblastoma. Med Pediatr Oncol. 2001 Jan;36(1):220-3. doi: 10.1002/1096-911X(20010101)36:13.0.CO;2-6.</citation>
    <PMID>11464889</PMID>
  </results_reference>
  <verification_date>May 2007</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>May 11, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2004</study_first_posted>
  <last_update_submitted>December 18, 2013</last_update_submitted>
  <last_update_submitted_qc>December 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 19, 2013</last_update_posted>
  <keyword>localized resectable neuroblastoma</keyword>
  <keyword>regional neuroblastoma</keyword>
  <keyword>disseminated neuroblastoma</keyword>
  <keyword>stage 4S neuroblastoma</keyword>
  <keyword>localized unresectable neuroblastoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cobalt</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
    <mesh_term>Dacarbazine</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Vindesine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

